Analyst Price Targets — QDEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 7, 2026 12:15 pm | Lu Li | UBS | $12.00 | $10.74 | TheFly | QuidelOrtho price target lowered to $12 from $17 at UBS |
| May 7, 2026 9:10 am | Tycho Peterson | Jefferies | $12.50 | $10.96 | TheFly | QuidelOrtho downgraded to Hold from Buy at Jefferies |
| April 10, 2026 11:35 am | — | UBS | $17.00 | $13.94 | TheFly | QuidelOrtho price target lowered to $17 from $30 at UBS |
| February 12, 2026 2:29 pm | — | UBS | $30.00 | $23.19 | TheFly | QuidelOrtho price target lowered to $30 from $35 at UBS |
| January 21, 2026 11:20 am | — | UBS | $35.00 | $32.73 | TheFly | QuidelOrtho price target raised to $35 from $31 at UBS |
| September 19, 2024 8:37 am | Lu Li | UBS | $50.00 | $46.23 | TheFly | QuidelOrtho assumed with Neutral from Sell at UBS |
| September 5, 2024 7:26 am | Bill Bonello | Craig-Hallum | $57.00 | $42.93 | StreetInsider | Craig-Hallum Upgrades Quidel Corp. (QDEL) to Buy |
| August 15, 2023 3:08 pm | Andrew Cooper | Raymond James | $110.00 | $74.47 | Benzinga | Analyst Is Frustrated By QuidelOrtho's Reduction In Guidance - Here's Why |
| December 12, 2022 7:28 am | — | Citigroup | $125.00 | $92.30 | Benzinga | Citigroup Upgrades QuidelOrtho to Buy, Raises Price Target to $125 |
| December 7, 2022 4:43 am | — | RBC Capital | $125.00 | $92.19 | Benzinga | RBC Capital Initiates Coverage On QuidelOrtho with Outperform Rating, Announces Price Target of $125 |
Latest News for QDEL
SAN DIEGO, July 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of restricted stock units ("RSUs") with respect to 356,555 shares of the Company's common stock (the "Inducement Grant") to Micah Young, the Company's Chief Financial…
QuidelOrtho Corporation continues its steep decline, with over 40% losses since February and a $5B market cap drop since its 2022 merger. QDEL's Q4 and Q1 results both disappointed, with 2026 EPS guidance cut twice in three months and consensus now at $1.85 per share. Profitability struggles are compounded by rising debt, high inventory, weak Chinese sales, and a soft respiratory season, with no clear mitigation…
QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Seasoned medical technology finance executive brings more than two decades of leadership at global public companies SAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company"), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M.
QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QDEL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.